Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy
Cancers · 21.01.2023 · 15 (3) · 666
DOI: 10.3390/cancers15030666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.01.2023. Verfasst von Xiaoxia Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Science, Henan University, Kaifeng 475004, China. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key R&D and Promotion Projects in Henan Province, Key Scientific Research Projects of Colleges and Universities in Henan Province.
Abstract (Originalsprache)
Cancer is one of the leading causes of death and the most important impediments to the efforts to increase life expectancy worldwide. Currently, chemotherapy is the main treatment for cancer, but it is often accompanied by side effects that affect normal tissues and organs. The search for new alternatives to chemotherapy has been a hot research topic in the field of antineoplastic medicine. Drugs targeting diseased tissues or cells can significantly improve the efficacy of drugs. Therefore, organelle-targeted antitumor drugs are being explored, such as mitochondria-targeted antitumor drugs. Mitochondria is the central site of cellular energy production and plays an important role in cell survival and death. Moreover, a large number of studies have shown a close association between mitochondrial metabolism and tumorigenesis and progression, making mitochondria a promising new target for cancer therapy. Combining mitochondrial targeting agents with drug molecules is an effective way of mitochondrial targeting. In addition, hyperpolarized tumor cell membranes and mitochondrial membrane potentially allow selective accumulation of mitochondria-targeted drugs. This enhances the direct killing of tumor cells by drug molecules while minimizing the potential toxicity to normal cells. In this review, we discuss the common pro-mitochondrial agents, the advantages of triphenylphosphine (TPP) in mitochondrial-targeted cancer therapy and systematically summarize various TPP-based mitochondria-targeting anticancer drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medical Science, Henan University, Kaifeng 475004, China.
- School of Clinical Medicine, Henan University, Kaifeng 475004, China.
ORCID-Profile: Lei Zhang
Förderung
- National Natural Science Foundation of China
- Key R&D and Promotion Projects in Henan Province
- Key Scientific Research Projects of Colleges and Universities in Henan Province
- Kaifeng Science and Technology Development Plan
- National College Students' Innovation and Entrepreneurship Training Program
- Key R&D and Promotion Projects in Henan Province
- National College Students’ Innovation and Entrepreneurship Training Program
Zitieren
APA
Cheng, X., Feng, D., Lv, J., Cui, X., Wang, Y., Wang, Q., & Zhang, L. (2023). Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy. Cancers, 15(3), 666. https://doi.org/10.3390/cancers15030666
Vancouver
Cheng X, Feng D, Lv J, Cui X, Wang Y, Wang Q, et al. Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy. Cancers. 2023;15(3):666. doi:10.3390/cancers15030666
BibTeX
@article{Cheng2023,
author = {Cheng, Xiaoxia and Feng, Dong and Lv, Junyu and Cui, Xiaoman and Wang, Yichen and Wang, Qun and Zhang, Lei},
title = {Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {666},
doi = {10.3390/cancers15030666}
}
EUVIMED